Payment overview · 2025
General Payments
$29.75
1 reported records · 1 companies
Healthcare provider profile · identity verified
Tomasz Michalski, MD
Allopathic & Osteopathic Physicians|Family Medicine · STURGEON BAY, WI · NPI 1639393044
Verified facts
What the public records show
CMS Open Payments records show Tomasz Michalski, MD received $29.75 in general payments during 2025 across 1 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 305 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.75 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $29.75 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABILIFY Normalized: abilify |
Drug | E.R. Squibb & Sons, L.L.C. | $29.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
305 | 61 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 906 | 229 |
| Levothyroxine Sodium | Levothyroxine Sodium | 583 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 426 | 112 |
| Omeprazole | Omeprazole | 423 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 398 | 121 |
| Lisinopril | Lisinopril | 358 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 95 |
| Eliquis | Apixaban | 305 | 61 |
| Metformin Hcl | Metformin Hcl | 281 | 67 |
| Gabapentin | Gabapentin | 258 | 71 |
| Furosemide | Furosemide | 249 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 61 |
| Losartan Potassium | Losartan Potassium | 232 | 58 |
| Valsartan | Valsartan | 218 | 54 |
| Simvastatin | Simvastatin | 217 | 57 |
| Chlorthalidone | Chlorthalidone | 203 | 48 |
| Ozempic | Semaglutide | 202 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 40 |
| Tramadol Hcl | Tramadol Hcl | 155 | 32 |
| Ezetimibe | Ezetimibe | 152 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 53 |
| Metformin Hcl Er | Metformin Hcl | 137 | 44 |
| Sertraline Hcl | Sertraline Hcl | 135 | 35 |
| Carvedilol | Carvedilol | 134 | 36 |
| Allopurinol | Allopurinol | 128 | 38 |
| Atenolol | Atenolol | 122 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 33 |
| Meloxicam | Meloxicam | 110 | 29 |
| Trulicity | Dulaglutide | 108 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 108 | 32 |
| Warfarin Sodium | Warfarin Sodium | 107 | 25 |
| Spironolactone | Spironolactone | 104 | 25 |
| Potassium Chloride | Potassium Chloride | 103 | 35 |
| Trazodone Hcl | Trazodone Hcl | 93 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 26 |
| Pregabalin | Pregabalin | 92 | 14 |
| Alprazolam | Alprazolam | 85 | 28 |
| Donepezil Hcl | Donepezil Hcl | 82 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 26 |
| Irbesartan | Irbesartan | 76 | 14 |
| Lovastatin | Lovastatin | 75 | 21 |
| Glipizide Er | Glipizide | 70 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 17 |
| Prednisone | Prednisone | 59 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Mirtazapine | Mirtazapine | 55 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 16 |
| Xarelto | Rivaroxaban | 52 | 16 |
| Finasteride | Finasteride | 50 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 11 |
| Alendronate Sodium | Alendronate Sodium | 47 | 16 |
| Famotidine | Famotidine | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 12 |
| Benazepril Hcl | Benazepril Hcl | 40 | 12 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Calcitriol | Calcitriol | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Diazepam | Diazepam | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $29.75 · 1 records | E.R. Squibb & Sons, L.L.C. | ABILIFY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error